Drug Profile
Research programme: CCR5 antagonists - Incyte
Latest Information Update: 04 Feb 2011
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Small molecules
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Viral infections
Most Recent Events
- 30 Apr 2008 Incyte's CCR5 antagonist programme is available for licensing (http://www.incyte.com)
- 12 Jul 2006 Preclinical trials in Viral infections in USA (unspecified route)